Protalix Biotherapeutics, Inc. (PLX)
2.525
+0.04
(+1.81%)
USD |
NYAM |
Oct 27, 15:27
Protalix Biotherapeutics Market Cap : 203.44M for Oct. 27, 2026
Market Cap Chart
Historical Market Cap Data
| Date | Value |
|---|---|
| October 26, 2026 | 199.82M |
| October 23, 2026 | 205.46M |
| October 22, 2026 | 207.07M |
| October 21, 2026 | 207.07M |
| October 20, 2026 | 212.71M |
| October 19, 2026 | 206.26M |
| October 16, 2026 | 211.10M |
| October 15, 2026 | 217.54M |
| October 14, 2026 | 210.29M |
| October 13, 2026 | 221.57M |
| October 12, 2026 | 223.99M |
| October 09, 2026 | 223.99M |
| October 08, 2026 | 217.54M |
| October 07, 2026 | 218.35M |
| October 06, 2026 | 219.96M |
| October 05, 2026 | 218.35M |
| October 02, 2026 | 218.35M |
| October 01, 2026 | 215.93M |
| September 30, 2026 | 222.38M |
| September 29, 2026 | 216.74M |
| September 28, 2026 | 216.74M |
| September 25, 2026 | 219.15M |
| September 24, 2026 | 221.57M |
| September 23, 2026 | 225.60M |
| September 22, 2026 | 228.82M |
| Date | Value |
|---|---|
| September 21, 2026 | 221.57M |
| September 18, 2026 | 216.74M |
| September 17, 2026 | 217.54M |
| September 16, 2026 | 215.93M |
| September 15, 2026 | 214.32M |
| September 14, 2026 | 223.18M |
| September 11, 2026 | 212.71M |
| September 10, 2026 | 219.96M |
| September 09, 2026 | 215.13M |
| September 08, 2026 | 213.51M |
| September 04, 2026 | 215.13M |
| September 03, 2026 | 211.10M |
| September 02, 2026 | 208.68M |
| September 01, 2026 | 208.68M |
| August 31, 2026 | 207.07M |
| August 28, 2026 | 204.65M |
| August 27, 2026 | 210.29M |
| August 26, 2026 | 199.82M |
| August 25, 2026 | 193.37M |
| August 24, 2026 | 194.18M |
| August 21, 2026 | 191.76M |
| August 20, 2026 | 191.76M |
| August 19, 2026 | 189.34M |
| August 18, 2026 | 188.54M |
| August 17, 2026 | 184.51M |
Market Capitalization Definition
Market Capitalization measures the total value of a company based on their stock price multiplied by the shares outstanding. This metric is important because it gives you an idea of the size of a company, and how the size has changed over time. When studying companies from a relative basis, it would make sense to compare companies that have a similar market capitalization because factors like market share, economies of scale, and business models would also be similar.
Market Cap Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Market Cap Benchmarks
| Altimmune, Inc. | 395.75M |
| Taysha Gene Therapies, Inc. | 1.379B |
| Humacyte, Inc. | 122.81M |
| Agenus, Inc. | 273.17M |
| Amgen, Inc. | 241.22B |
Market Cap Related Metrics
| PE Ratio | 11.12 |
| PS Ratio | 2.559 |
| PEG Ratio | 0.0538 |
| Price to Book Value | 2.849 |
| Price to Free Cash Flow | 26.91 |
| Price | 2.525 |
| Earnings Yield | 8.99% |
| PEGY Ratio | 0.0538 |
| Operating PE Ratio | 8.858 |
| Normalized PE Ratio | 11.12 |